Catyalyst Pharmaceutical Partners (CPRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results
August 14, 2014 8:03 AM EDTCORAL GABLES, Fla., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc., stated, "As we announced earlier this week, we reached a major inflection point recently as the last patient in our Phase 3 trial completed the double-blind, placebo-controlled portion of our trial, and we remain on track to... More
